72 related articles for article (PubMed ID: 9133079)
1. [Results and perspectives in the chemoprophylaxis of cancer].
Aleksandrov VA
Vopr Onkol; 1997; 43(1):124-9. PubMed ID: 9133079
[No Abstract] [Full Text] [Related]
2. The critical role of risk-benefit assessments in cancer prevention.
Hawk E; Viner JL
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):297-8. PubMed ID: 15734949
[No Abstract] [Full Text] [Related]
3. Clinical development plan: l-Selenomethionine.
J Cell Biochem Suppl; 1996; 26():202-18. PubMed ID: 9154178
[No Abstract] [Full Text] [Related]
4. Clinical development plan: sulindac sulfone.
J Cell Biochem Suppl; 1996; 26():227-35. PubMed ID: 9154180
[No Abstract] [Full Text] [Related]
5. Clinical development plan: 13-cis-retinoic acid.
J Cell Biochem Suppl; 1996; 26():168-201. PubMed ID: 9154177
[No Abstract] [Full Text] [Related]
6. Chemoprevention clinical trials: it is time to turn success into progress.
Brown PH
Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1531-2. PubMed ID: 17684123
[No Abstract] [Full Text] [Related]
7. Clinical development plan: vitamin A.
J Cell Biochem Suppl; 1996; 26():269-307. PubMed ID: 9154183
[No Abstract] [Full Text] [Related]
8. Lycopene in cancer prevention and treatment.
Seren S; Lieberman R; Bayraktar UD; Heath E; Sahin K; Andic F; Kucuk O
Am J Ther; 2008; 15(1):66-81. PubMed ID: 18223356
[TBL] [Abstract][Full Text] [Related]
9. Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
Vanchieri C
J Natl Cancer Inst; 2005 Apr; 97(8):552-3. PubMed ID: 15840872
[No Abstract] [Full Text] [Related]
10. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
Armstrong WB; Taylor TH; Meyskens FL
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
[No Abstract] [Full Text] [Related]
11. The convergent development of molecular-targeted drugs for cancer treatment and prevention.
Lippman SM; Heymach JV
Clin Cancer Res; 2007 Jul; 13(14):4035-41. PubMed ID: 17634526
[TBL] [Abstract][Full Text] [Related]
12. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.
Kelloff GJ; O'Shaughnessy JA; Gordon GB; Hawk ET; Sigman CC
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):593-6. PubMed ID: 12869396
[No Abstract] [Full Text] [Related]
13. Clinical development plan: dehydroepiandrosterone (DHEA).
J Cell Biochem Suppl; 1996; 26():86-99. PubMed ID: 9154170
[No Abstract] [Full Text] [Related]
14. Lessons learned from lung cancer chemoprevention trials.
Kim ES
Nat Clin Pract Oncol; 2009 Jan; 6(1):1. PubMed ID: 19096395
[No Abstract] [Full Text] [Related]
15. Clinical trials. Nail-biting time for trials of COX-2 drugs.
Couzin J
Science; 2004 Dec; 306(5702):1673-5. PubMed ID: 15576585
[No Abstract] [Full Text] [Related]
16. Despite positive studies, popularity of chemoprevention drugs increasing slowly.
Zielinski SL
J Natl Cancer Inst; 2004 Oct; 96(19):1410-2. PubMed ID: 15467023
[No Abstract] [Full Text] [Related]
17. Clinical development plan: 1,4-penylenebis(methylene)selenocyanate.
J Cell Biochem Suppl; 1996; 26():219-26. PubMed ID: 9154179
[No Abstract] [Full Text] [Related]
18. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview.
Crowell JA
Eur J Cancer; 2005 Sep; 41(13):1889-910. PubMed ID: 16005206
[TBL] [Abstract][Full Text] [Related]
19. Prevention--therapy--basic science and the resolution of the cancer problem.
Wattenberg LW
Cancer Res; 1993 Dec; 53(24):5890-6. PubMed ID: 8261399
[No Abstract] [Full Text] [Related]
20. Statins and prostate cancer.
Harv Mens Health Watch; 2009 May; 13(10):6-7. PubMed ID: 19489154
[No Abstract] [Full Text] [Related]
[Next] [New Search]
